ArticleVirology journal2025
Optimizing steroid treatment for UC patients with CMV colitis: a multicenter real-world study.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundUlcerative colitis (UC) patients with concomitant cytomegalovirus (CMV) colitis face higher disease activity and poorer prognosis. While antiviral therapy improves outcomes, optimal immunosuppressive management during treatment remains controversial, particularly regarding steroid use.
methodsIn this two-center retrospective study, hospitalized patients with moderate-to-severe UC with concomitant CMV colitis from January, 2013 to February, 2024 were stratified into stratified into three groups by steroid strategy post-CMV diagnosis: intensified treatment, steroid tapering, and steroid non-initiation. Primary outcome was colectomy on Week 26 since the diagnosis of CMV colitis. Secondary outcome included clinical response and remission on the 7th and 14th day, and colectomy on Week 52. Multivariate logistic regression adjusted for confounders was used for analysis.
resultsBaseline steroid cumulative dose differed significantly across groups: highest in the tapering group (2.2 ± 2.0 g), intermediate in the intensified group (0.6 ± 1.2 g), and absent in the non-initiation group (0 g, all P < 0.001). After adjustment, the intensified group had a significantly lower Week 26 colectomy risk vs. non-initiation (adjusted OR = 0.1, 95%CI = 0.02-0.9, P = 0.035) and higher Day 7 clinical response (adjusted OR = 4.5, 95%CI = 1.1-18.9, P = 0.041); Day 7 remission trended higher but was not significant (adjusted OR = 14.1, 95%CI = 0.9-213.9, P = 0.057). At Week 52, the intensified group still had lower colectomy risk vs. non-initiation (adjusted OR = 0.1, 95%CI = 0.02-0.9, P = 0.040). No significant differences in short- or long-term outcomes were observed between the intensified and tapering groups.
conclusionSteroid strategies for UC with CMV colitis require context-specific adjustments based on baseline steroid exposure. Intensified treatment outperforms steroid non-initiation in improving short-term response and reducing long-term colectomy risk, while showing no inferiority to tapering. Individualized therapy balancing immediate and long-term outcomes is critical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.